Diabetic Macular Edema

Diabetic retinopathy can cause swelling of the center of the retina, the macula, and vision loss.

What is a Diabetic Macular Edema

Diabetic macular edema is swelling in the retina associated with diabetes. This swelling can blur and distort the vision. The swelling occurs because the walls of the small blood vessels are progressively more damaged in diabetes, and there is leakage of blood and fluid into the cells of the retina. There are a variety of options to treat diabetic macular edema. The oldest treatment is laser for retinal swelling. It has been studied for decades and has been shown to be safe and effective. As with all treatments, it is not curative, and it is not without risk, but laser is one of the safest things that we do in diabetic retinal care. Other newer treatments for diabetic retinal swelling have been shown to improve vision even more than laser in some cases, and have also been shown to be safe and effective in large modern trials. These treatments are a variety of injections given into the eye in the office, and they are sometimes given alone and sometimes given with laser in addition. There are two major classes of injections used in diabetic macular edema, and those are small molecule injections and corticosteroid injections. The injections work in different ways to reduce the leakage and swelling in the retina, and sometimes the different types of injections are both used. The injections are administered under local anesthesia, and are often relatively well-tolerated by patients. Injections are also amongst the safest procedures performed in the retinal clinic, and the specific risks and benefits of injections will be discussed by your doctor. Most patients with blurred vision from diabetic macular edema enjoy an improvement in vision with treatment. Often, treatment to maintain vision is ongoing, and the long-term treatment plan is individualized to each specific patient in our practice.

What is a Laser?

When diabetic macular edema is caused by focal areas of leakage, laser treatment can be helpful. Studies were done in the 1980's validating the use of laser to reduce the risk of vision loss and improve vision in patients with diabetic macular edema. The advantage of laser of intravitreal injections is that laser treatment usually only needs to be repeated a few times. Intravireal injections are given monthly. The disadvantage of laser, is that it does not improve vision as much as intravitreal injections do when the center of the macula is swollen. Many physicians will use both laser and intravitreal injections depending on the area of the macula that is swollen and the findings on examination and testing.

Lucentis for Diabetic Macular Edema

Monthly Lucentis therapy is helpful for patients with diabetic macular edema. With laser only, about 15 percent of patients have substantial visual improvement at 2 years. With Lucentis therapy, about 40 percent of patients have a substantial improvement in visual acuity. Subsequent studies have shown that ongoing monthly treatment is usually not necessary to maintain the visual benefit.


Diabetic Macular Edema NEWS

Below are current articles from a Google News Feed on Diabetic Macular Edema

Alimera Sciences wins Health Canada nod for diabetic macular edema implant  Mass Device

Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema. The Iluvien ...

Single Retinal Layer Changes After Subthreshold Micropulse Yellow Laser in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | A pilot prospective, interventional study has been conducted on 10 patients with diabetic macular edema ...

Dr. Mali's top 5 stories in ophthalmology for 2018  Ophthalmology Times

It's that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology ...

Safety of high-dose intravitreal triamcinolone acetonide as low-cost a | OPTH  Dove Medical Press

Hammouda Hamdy Ghoraba,1,2 Mahmoud Leila,3 Sameh Mohamed Elgouhary,4 Emad Eldin Mohamed Elgemai,2,5 Haithem Mamon Abdelfattah,2,6 Hashem ...

Daily Research News Online no. 27214 - Ipsos Launches Ophthalmology Monitor  Daily Research News Online

Ipsos has launched a Global Ophthalmology Therapy Monitor - the latest addition to its Syndicated Real World Evidence Portfolio - in the big five EU markets ...

OPT-302 Improves Acuity in Combination with Aflibercept  MD Magazine

Patients with diabetic macular edema who do not show sufficient progress after anti-VEGF-A treatment may soon have a new option.

Diabetes and the eyes  KPLC

People with diabetes are at a higher risk for issues in the eye than those without the disease.

Diabetic Macular Edema Drug Market Estimations and Trends Through 2025  Chesco DOES

“Global Diabetic Macular Edema Drug Market Research Report 2018-2025” This report researches the worldwide Diabetic Macular Edema Drug Market size ...

High-Dose ITVA Found Considered Safe, Cost-Effective Alternative to Anti-VEGF  MD Magazine

A new study finds high-dose intravitreal triamcinolone acetonide is a safe alternative to anti-vascular endothelial growth factor, a finding that is welcome news for ...

Health Canada approves Iluvien for DME  Healio

Iluvien has been approved by Health Canada, Alimera Sciences announced in a press release.A fluocinolone acetonide sustained-release intravitreal implant, ...

Knight Therapeutics Announces Canadian Regulatory Approval for ILUVIEN®  GlobeNewswire

MONTREAL, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, ...

BLOG: Top five things to know about an innovative drug delivery system for DME  Healio

Ophthalmology Blogs | Mali | Standard therapy for the rising number of patients with diabetic macular edema typically consists of anti-VEGF treatments. However ...

Diabetic Macular Edema Treatment Market Research On Competition Landscape 2018 & 2019: GSK, Alimera Sciences, Allergan, Regeneron Pharmaceuticals, Inc., Pfizer, Bayer, Roche, Novartis, Acucela Inc., Oculis, Bausch + Lomb, Jaeb Center for Health Research  openPR

Diabetic Macular Edema Treatment Market Research Provides the “How Market potential for each geographical region based on the growth rate, ...

KalVista Pharmaceuticals Reports Fiscal Second Quarter Results  Business Wire

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of.

Diabetic Macular Edema (DME) Market-Symptoms, Treatment and Definition Forecast to 2027  Journal of Industry

Diabetic Macular Edema (DME) – Market Insights, Epidemiology and Market Forecast 2027 report provides the detailed overview of the disease and in depth ...

Diabetic Macular Edema Treatment Market 2018-2022: Growth Rate, Players, Regions, Opportunities, Developments  DigiTribune

Diabetic Macular Edema Treatment market report delivers comprehensive global industry intelligence through detailed segmentation, market size and forecasts, ...

Diabetic 22-year-old in Vanuatu hopes skin graft will save her leg  New Zealand Herald

Fit woman from Pentecost Island at risk of losing leg and eyesight due to Type 1 diabetes.

Diabetic Macular Edema Treatment Market: Business Opportunities, Current Trends and Restraints Forecast 2022 – All  All For Updates

Diabetic Macular Edema Treatment Market report is the believable source for gaining the market research that will exponentially accelerate your business.

Diabetic Macular Edema Market will Reach Nearly US$ 4100 Mn by 2027  Find Market Research By Abhishek Budholiya

The global diabetic macular edema (DME) market is projected to register a sluggish expansion at 1.1% CAGR through 2027, according to a report by Future ...

Diabetic Macular Edema Treatment Market Research On Impressive Growth In 2019 To 2025 By: Bayer, Roche, Novartis, GSK, Alimera Sciences, Allergan, Regeneron Pharmaceuticals, Inc., Pfizer, Acucela Inc., Oculis, Bausch + Lomb, Jaeb Center for Health Researc  openPR

The Diabetic Macular Edema Treatment Market is increasing the forecast years of 2019-2025 and pulling the industry with it. It helps in imagining the ...

Characteristics of diabetic macular edema on optical coherence tomogra | OPTH  Dove Medical Press

Characteristics of diabetic macular edema on optical coherence tomography may change over time or after treatment Shwu-Jiuan Sheu,1,2 Ying-Yen Lee,1 ...

Diabetic Macular Edema Drug Sales Market Forecast – Industry Value, Market Size, Top Companies and General Trends for 2018-2025  Island Post Gazette

Global Diabetic Macular Edema Drug Sales Market report describes elements such as dominating companies, types, applications, classification, size, SWOT ...

Diabetic Eye Disease: A Leading Cause of Blindness - Flagstaff Business & Online News | Northern Arizona Local Newspaper  Flagstaff Business News

November is National Diabetes Month, when communities join to bring awareness to the disease. From an eye care standpoint, diabetic eye disease is a ...

Diabetic Macular Edema Market is expected to CAGR of 1.1% over the forecast period of 2017– 2027  Latest Market Reports By Abhishek Budholiya

Market Insights forecasts the global diabetic macular edema market to grow from nearly US$ 3,710 Mn in 2017 to over US$ 4,100 Mn by 2027 end.

Diabetic Macular Edema Drug Market Growth 2018- 2025: Industry Size, Share, Trend, Major Manufactures & Business Insight  The Future Gadgets

The latest report on Diabetic Macular Edema Drug market offers detailed information about the industry based on the total revenue generated for the forecast ...

Treatment patterns in diabetic macular edema in Taiwan: a retrospectiv | OPTH  Dove Medical Press

Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review Shwu-Jiuan Sheu,1,2 Cheng-Kuo Cheng,3,4 Hsi-Kung Kuo,5 Ching-Yao ...

Anti-VEGF Effective in Persistent Diabetic Macular Edema  Medscape

A recent analysis associated three different anti-VEGF agents with meaningful vision gains through 2 years of follow-up.

KOD For The Long Haul, GMDA Turning Heads, TNDM Jumps On Analyst Upgrade  Nasdaq

The Company went public on the Nasdaq Global Market on October 4, 2018, offering its shares at a price of $10.00 each. The net loss for the third.

BLOG: Systemic disease can affect cataract surgery outcomes  Healio

Optometry Blogs | Alldredge Brooks | As eye care providers, we all know that we are treating the patient in our chair and not an isolated eyeball. However, it is ...

KOD Catches Eyes, MRNS On Watch, Mark Your Calendar For AQST  Nasdaq

Gained 22.37% to close Thursday's trading at $9.30. The Company went public on the Nasdaq Global Market on October 4, 2018, offering its shares at a.

Battling superstition - the life of a Fred Hollows Foundation eye nurse in Vanuatu  New Zealand Herald

This Christmas, the Herald and The Fred Hollows Foundation NZ are working together to bring the Gift of Sight to the Pacific, where four out of five people who ...

First Republic Investment Management Inc. Reduces Stake in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

First Republic Investment Management Inc. decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.6% during the 3rd quarter, ...

Theravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York  Odessa American

DUBLIN, Dec. 4, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") will host an R&D Day from ...

Regeneron (REGN) Rides on Eylea and Dupixent's Performance  Zacks.com

Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.

ThromboGenics completes first trial for new diabetic macular edema drug  Labiotech.eu

Belgian biotech ThromboGenics has conducted the first clinical trial of an antibody to treat one of the world's leading causes of vision loss.

Diabetic Retinopathy Market : Exclusive Compititors Profiles: Allergan, Novartis, Bayer, Genentech and Regeneron Pharmaceuticals - Press Release  Digital Journal

Increasing geriatric population base coupled with rising incidences of age related macular degeneration (AMD) and diabetes will drive diabetic retinopathy ...

Risuteganib complements anti-VEGF treatment for diabetic macular edema  Healio

VIENNA — Integrin inhibitor risuteganib was effective in complementing the anti-VEGF pathway when administered sequentially to an anti-VEGF drug in patients ...

Kodiak Sciences pushes ahead with trials for diabetic eye disease drug as it unveils 3Q results  Proactive Investors USA & Canada

Kodiak Sciences Inc (NASDAQ:KOD) - Kodiak's IPO just last month raised $94m in gross proceeds, which is being put towards funding its research.

Recon: HHS Defends Drug Pricing Proposal; Mallinckrodt to Spin Off Specialty Generics Business  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Highly Anticipated Moderna Listing Is Seen As Test ...

CPAP for OSA Does Not Improve Diabetic Macular Edema or Visual Acuity  Pulmonology Advisor

Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) in patients with type 2 diabetes mellitus (T2DM) and diabetic macular ...

Momenta (MNTA) Down 16.7% Since Last Earnings Report: Can It Rebound?  Nasdaq

It has been about a month since the last earnings report for Momenta Pharmaceuticals (MNTA). Shares have lost about 16.7% in that time frame,.

Relationship Between Dry Retinal Volume and Visual Acuity in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the relationship between a novel spectral-domain optical ...

Kalvista Pharmaceuticals (KALV) Announces Earnings Results  Fairfield Current

Kalvista Pharmaceuticals (NASDAQ:KALV) released its earnings results on Friday. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, ...

Awards, Posters, and Participation by NECO at Academy 2018 | News  New England College of Optometry

New England College of Optometry (NECO) students, faculty, alumni, professional staff, and residents delivered presentations, posters, research, and lectures ...

KalVista To Pioneer Plasma Kallikrein Inhibitor Therapy For Diabetic Macular Edema  Seeking Alpha

Anti-VEGF therapy for diabetic macular edema (DME) is heralded as a miracle treatment. Granted, but there exists a significant subset of minimally- or ...

IBD 50 Stocks To Watch: A Base Among Biotech Stocks  Investor's Business Daily

Biotech stocks aren't exactly setting the world on fire as the stock market wades through a tough stretch. But a few, like Regeneron Pharmaceuticals (REGN), ...

Diabetic Macular Edema Drug Market Movement – Detailed Research and Analysis Report, CAGR 2018 to 2023  TokeNexa

Researchvector present the report on Global Diabetic Macular Edema Drug Market evaluates the growth trends of the industry through historical study and ...

Diabetic Macular Edema Drug Market Value with top competitiors : Novartis, Bayer, Allergan, Hoffman-La Roche  SportsSpring

Marketresearchpro shared “Diabetic Macular Edema Drug Market Information” which Provides Key Manufacturers, Key Profiles, Strategies and Forecast Trends ...

Eye Drug Continues to Drive Regeneron's Growth  GuruFocus.com

Eye Drug Continues to Drive Regeneron's Growth, Stocks: REGN,NVS,RHHBY,XTER:BAYN,IBB,RGNX,APLS,OPHT,AGN, release date:Dec 04, 2018.

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

How strong man Karlpat was brought down by diabetes  New Zealand Herald

This Christmas, the Herald and The Fred Hollows Foundation NZ are working together to bring the Gift of Sight to the Pacific, where four out of five people who ...

Alimera Sciences (ALIM) Appoints Rick Eiswirth as CEO; Co-founder Dan Myers Named Non-Executive Chairman  StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Alimera Sciences, Inc. (NASDAQ: ALIM) ...

Analysts Set Alimera Sciences Inc (ALIM) Price Target at $2.50  Fairfield Current

Shares of Alimera Sciences Inc (NASDAQ:ALIM) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the firm, ...

Vanuatuan diabetes patient seeks eye surgery from Fred Hollows Foundation  New Zealand Herald

This Christmas, the Herald and The Fred Hollows Foundation NZ are working together to bring the Gift of Sight to the Pacific, where four out of five people who ...

Head to Head Survey: Clearside Biomedical (CLSD) vs. KemPharm (KMPH)  Fairfield Current

Clearside Biomedical (NASDAQ:CLSD) and KemPharm (NASDAQ:KMPH) are both small-cap medical companies, but which is the superior investment? We will ...

4 Vision Loss Causes Not Related to Age  Bel Marra Health

Here are four eye conditions which can trigger vision loss and are not related to your age.

Pacific bears the brunt of diabetes epidemic  New Zealand Herald

This Christmas, the Herald and The Fred Hollows Foundation NZ are working together to bring the Gift of Sight to the Pacific, where four out of five people who ...

Tuesday's small-cap stocks to watch  The Globe and Mail

Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.

Global Diabetic Macular Edema Treatment Market 2018-2022 - Key Vendors are Allergan Alimera Sciences, Bausch Health, F. Hoffmann-La Roche & Regeneron Pharmaceuticals  PR Newswire

DUBLIN, Sept 11, 2018 /PRNewswire/ -- The "Global Diabetic Macular Edema Treatment Market 2018-2022" report has been added to ...

The efficacy and safety of aflibercept and conbercept in diabetic macu | DDDT  Dove Medical Press

The efficacy and safety of aflibercept and conbercept in diabetic macular edema Siwei Cai, Qianhui Yang, Xiaorong Li, Yan Zhang Tianjin Medical University ...

Future Of Diabetic Macular Edema Market 2018: Key Companies Industry Insights And Current Global Market Trends 2022  The Industry Chronicle

A Research Report on Diabetic Macular Edema Market Potential Growth, Share, Demand and Analysis of Key Players – Research Forecasts to (2018 - 2022).

Pro-Charming Shoppes Inc Big Money Sentiment Runs Low in 2018 Q3, Currently at 1.11  The EN Bulletin

“Big money sentiment for Charming Shoppes Inc (NASDAQ:CHRS) in Q3 2018 decreased to 1.11, SEC.gov filings reveal. That's down -1.17, from 2018Q2's 2.28 ...

Opthea to Host Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum in New York City  GlobeNewswire

MELBOURNE, Australia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye ...

Biomarkers May Predict Rx Response in Diabetic Macular Edema  Medscape

Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, ...

Case Report on DME | Medpage Today  MedPage Today

An unexpected resolution of diabetic macular edema.

A day at the eye clinic  New Zealand Herald

This Christmas, the Herald and The Fred Hollows Foundation NZ are working together to bring the Gift of Sight to the Pacific, where four out of five people who ...

World Diabetes Day 2018: What is diabetic macular edema? 5 superfoods to manage DME and improve eyesight  Times Now

World Diabetes Day, celebrated on November 14 every year, aims to raise awareness about diabetes prevention. And here are five superfoods that can help ...

Do Corticosteroids Improve Diabetic Macular Edema Outcomes?  Medscape

Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 ...

Global Diabetic Macular Edema Treatment Market 2018-2022| Use of New Laser Delivery Systems to Boost Demand| Technavio  Business Wire

The global diabetic macular edema treatment market 2018-2022 is expected to post a CAGR of over 1% during the forecast period, according to Technavio.

Big Money Are Crazy About Iridex Corp (NASDAQ:IRIX), Sentiment at 1.78  The EN Bulletin

In Q3 2018 Iridex Corp (NASDAQ:IRIX) big money sentiment increased to 1.78, SEC filings reveal. So its up 0.98, from 2018Q2's 0.8. 16 hedge funds started ...

Fear of blindness prompts Vanuatu sea voyage to Fred Hollows Foundation 'Outreach' clinic  New Zealand Herald

This Christmas, the Herald and The Fred Hollows Foundation NZ are working together to bring the Gift of Sight to the Pacific, where four out of five people who ...

Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals  The Motley Fool

Ascending and descending? That might be how some investors view Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron Pharmaceuticals ...

Interface Biologics Completes Pre-IND Meeting with US FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases  GlobeNewswire

TORONTO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science ...

IRIDEX Announces Departure of Chief Financial Officer and Reiterates Full Year 2018 Guidance  P&T Community

MOUNTAIN VIEW, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced Chief Financial Officer Atabak Mokari will ...

Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To describe the frequency and variation of intravitreal bevacizumab ...

Drugs for Diabetic Macular Edema Market Outlook, Opportunities and Forecasts Report 2018-2023  News Egypt

Key Audience of “Drugs for Diabetic Macular Edema Market”:Â Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and ...

Opthea Provides Update on Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum  GlobeNewswire

MELBOURNE, Australia, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye ...

Light Mask to Inhibit Dark Adaptation Does Not Prevent Diabetic Macular Edema Progression  Endocrinology Advisor

The CLEOPATRA study provides evidence that the light mask offered to prevent dark adaptation is not recommended as a treatment option for ...

Aflibercept for clinically significant diabetic macular edema: 12-mont | OPTH  Dove Medical Press

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice Rafael Campos Polo, Consuelo Rubio Sánchez, Diego ...

Opthea Confirms Final Patient Enrolment in Phase 2b Wet AMD Clinical Trial  GlobeNewswire

MELBOURNE, Australia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel ...

Ophthalmic Drugs Market 2018 Receives a Rapid Boost in Economy Due to High Emerging Demands with CAGR of 6.0% by Forecast to 2023 - Press Release  Digital Journal

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Ophthalmic Drugs Market ...

Interface Biologics Announces New VP, Business Development  Associated Press

TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science ...

EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary  GlobeNewswire

Industry veteran who brings over 25 years of legal expertise in the medical device industry to newly created position -. WATERTOWN, Mass., Nov. 27, 2018 ...

Prevalence of Persistent Diabetic Macular Edema: Bevacizumab vs Aflibercept or Ranibizumab  Endocrinology Advisor

For patients with diabetic macular edema, persistence is more likely with bevacizumab than with aflibercept or ranibizumab.

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Sellers Increased Their Shorts By 25.32%  K Reviewer

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) reported an increase of 25.32% in shares shorted. FINRA announced shares shorted of EYPT's total 3.41 ...

Clearside Biomedical (CLSD) Sets New 1-Year Low at $1.26  Modern Readers

Clearside Biomedical Inc (NASDAQ:CLSD) reached a new 52-week low on Thursday . The stock traded as low as $1.26 and last traded at $1.33, with a volume ...

EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial  BioSpace

TARRYTOWN, N.Y., Oct. 25, 2018 /PRNewswire/ --. First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening ...

Global Diabetic Macular Edema (DME) Market Epidemiology Research Report 2018  TokensJournal

Diabetic Macular Edema (DME)- Epidemiology market gives comprehensive study of the important industry players has been done to offer understandings into ...

Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:The purpose of this study is to compare cancellation and no-show rates in ...

Regeneron Pharmaceuticals Inc (REGN) Shares Bought by MML Investors Services LLC  Fairfield Current

MML Investors Services LLC grew its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 25.8% in the 3rd quarter, according to its most ...

Diabetic Macular Edema Treatment Market: Global Industry Analysis, Size, Demand, Growth, Trends, Forecast to 2026  Tampa Bay Review

Report Focus: The report 'Diabetic Macular Edema Treatment Global Trends, Estimates and Forecasts, 2018-2026' reviews the latest trends in Diabetic Macular ...

FDA Approves Genentech's Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy  Business Wire

First and only prefilled syringe treatment option FDA-approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME) ...

Study finds biomarker that predicts who responds best to common diabetic complication  Medical Xpress

Researchers at St. Michael's Hospital have found a biomarker from fluid in the eye that predicts which patients will respond best to current treatments for diabetic ...

FDA to Review Injection Treatment for Diabetic Retinopathy  Pharmacy Times

The FDA has accepted for review Regeneron Pharmaceuticals' supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat ...

CrowdReviews Partnered with Conference Series to Announce: CME Accredited 28th International Conference on Insights in Ophthalmology  PR.com

Naples, FL, December 07, 2018 --(PR.com)-- Lighting the Future of Ophthalmology Ophthalmology is the branch of medicine which deals with the treatment, ...

Opthea Doses First Patient in Phase 2a Trial for OPT-302 in Diabetic Macular Edema  GlobeNewswire

MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic ...

ICO Publishes New Guidelines for Diabetic Retinopathy  MD Magazine

Importantly, they are not directed toward ophthalmologists, but at general physicians and public healthcare professionals.

Comparing Aerpio Pharmaceuticals (ARPO) & Kalvista Pharmaceuticals (KALV)  Fairfield Current

Aerpio Pharmaceuticals (OTCMKTS:ARPO) and Kalvista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better investment?

Therapy applied directly inside the eye best for treating uveitic macular edema  Medical Xpress

Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of ...

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $2.57 Million Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Fairfield Current

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 21.5% ...

» Load more